TerminatedNCT04771299
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
This study evaluates the effectiveness of Cariprazine for people with bipolarity.
Medication studyAges 19–65Canada
Understand this study
What is this study about?
This study evaluates the effectiveness of Cariprazine for people with bipolarity.
Who could participate?
This study is for people with type I bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria apply.
- Listed locations
- VancouverSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 7, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1
- Sponsor
- Lakshmi N Yatham
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT04771299
- Official title
Show the full official title
Efficacy of Cariprazine in Improving Cognitive Functioning in Euthymic Patients With Bipolar I Disorder: A Proof of Concept Randomized, Double Blind Placebo Controlled Trial
Recruitment & locations
TerminatedVancouver
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the effectiveness of Cariprazine for people with bipolarity.
Who is behind this study?
The study sponsor is Lakshmi N Yatham.
Does this study involve medication?
Yes. The study involves medication, including Cariprazine.
Who can participate?
This study is for people with type I bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
